Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.

NCT00753454 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00753454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00753454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2008
Completion date
May 31, 2011
Enrollment
168 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis